about
DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinaseTrisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteinsA genetic cause of Alzheimer disease: mechanistic insights from Down syndromeStiffness of the large arteries in individuals with and without Down syndromeUnderstanding the basis for Down syndrome phenotypes.LDLR expression and localization are altered in mouse and human cell culture models of Alzheimer's diseaseToward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial.A cross-sectional study of the phenotypes of obesity and insulin resistance in adults with down syndromeIs Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?Risk of Major Cardiovascular Events in People with Down Syndrome.Sterol lipid metabolism in down syndrome revisited: down syndrome is associated with a selective reduction in serum brassicasterol levelsLipid profiles of children with Down syndrome compared with their siblings.Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.An integrative computational analysis provides evidence for FBN1-associated network deregulation in trisomy 21Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trialCardiovascular Disease, Single Nucleotide Polymorphisms; and the Renin Angiotensin System: Is There a MicroRNA Connection?Comorbidity in people with Down's syndrome: a criteria-based analysis.Low heart-type fatty acid binding protein level during aging may protect down syndrome people against atherosclerosis.Inflammatory and Immunological parameters in adults with Down syndromeCerebrovascular pathology in Down syndrome and Alzheimer disease.Does the association between serum endostatin, an endogenous anti-angiogenic protein, and acute myocardial infarction differ by race?Atherosclerotic Surrogate Markers in Adults With Down Syndrome: A Case-Control Study.Down syndrome and microRNAs.
P2860
Q21562345-8FF3215B-7052-4719-B417-CC6C3785F3AEQ24622025-580FCA6C-3AAF-4F74-A853-1E3C29955BB8Q26798983-5A81B5A4-DD94-410C-A131-02A1B90CE49EQ30474901-939510BE-AD02-4D42-BD78-50C76CF07B85Q33238943-19F6A6EA-85C6-4609-88B6-788A35146526Q33521909-81C06ECD-3504-4760-95F5-8E249E098773Q33770940-245075DB-ECAF-4FA0-95AB-1FC795F3D9BEQ34750070-B0FAA716-8464-462A-BD86-C6F5BD7B5C6FQ34917679-899EC045-BFCA-4000-BADC-4E06B032FE3FQ35793298-C36BAE61-1133-48C6-8D0D-023349E1BDDEQ35977501-D54EB371-6D82-43AB-A796-F510CE0BED29Q35996759-AB9BB7EF-6873-40C7-A8A0-7488D7A8D9EFQ36767734-EBC360C3-DC7E-4057-98ED-767AE6F0B4B4Q37096595-2A588780-B500-49B3-9D28-7EB917939A1BQ37102001-C6DD4A28-B4E1-486E-91E5-0A7C785B3B88Q37139026-F29676A2-0904-40E9-91DF-AAF617B6F6ACQ37800362-3866D260-260B-43F4-BFD4-87D18F8FCD22Q41201085-B20A11AD-9962-43BA-B52F-551FD2D066EDQ42022577-C65130BA-4057-4FC8-B4F8-D8AEE3183A20Q42150452-5151CF62-9DA6-49A9-A945-F9FF59C24479Q46317444-F407A66A-1C6E-4119-8F26-2589B57F6463Q46413991-4BADB4AC-6D17-46DE-AD7B-1526DFBB6B79Q48124681-6FBDDD40-061C-4C34-A4E0-ECDF9967DB2BQ49233869-D05F2CCC-CC40-4390-B4F8-71D8F7DFB768
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Down's syndrome and atherosclerosis.
@en
Down's syndrome and atherosclerosis.
@nl
type
label
Down's syndrome and atherosclerosis.
@en
Down's syndrome and atherosclerosis.
@nl
prefLabel
Down's syndrome and atherosclerosis.
@en
Down's syndrome and atherosclerosis.
@nl
P2093
P1433
P1476
Down's syndrome and atherosclerosis.
@en
P2093
P304
P356
10.1016/0021-9150(89)90110-X
P577
1989-04-01T00:00:00Z